ID   SJNB-7
AC   CVCL_8824
AS   CVCL_1449
SY   SJ-NB-7; SJNB7; NB7; NB7-DH; NCG; SJ-NCG
DR   BTO; BTO:0003439
DR   CLO; CLO_0037090
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 952
DR   cancercelllines; CVCL_8824
DR   Cell_Model_Passport; SIDM00156
DR   ChEMBL-Cells; CHEMBL3308158
DR   ChEMBL-Targets; CHEMBL2366345
DR   Cosmic; 688083
DR   Cosmic; 801748
DR   Cosmic; 949174
DR   Cosmic; 947717
DR   Cosmic; 1037337
DR   Cosmic; 1099134
DR   Cosmic; 1153798
DR   Cosmic; 2131587
DR   Cosmic-CLP; 949174
DR   DepMap; ACH-002285
DR   EGA; EGAS00001000978
DR   GDSC; 949174
DR   GEO; GSM314025
DR   GEO; GSM333812
DR   GEO; GSM1670155
DR   IARC_TP53; 27180
DR   LINCS_LDP; LCL-1997
DR   PharmacoDB; NB7_994_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_8824
DR   PubChem_Cell_line; CVCL_8824
DR   Wikidata; Q54953579
RX   DOI=10.1007/0-306-46872-7_2;
RX   PubMed=6171342;
RX   PubMed=8516298;
RX   PubMed=10935473;
RX   PubMed=15892104;
RX   PubMed=18923524;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.35%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=68.16%; European, South=31.49% (PubMed=30894373).
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 11,13
ST   D13S317: 8,13
ST   D16S539: 8,11
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 17,19
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   7M
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 34
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   PubMed=6171342;
RA   Brodeur G.M., Green A.A., Hayes F.A., Williams K.J., Williams D.L.,
RA   Tsiatis A.A.;
RT   "Cytogenetic features of human neuroblastomas and cell lines.";
RL   Cancer Res. 41:4678-4686(1981).
//
RX   PubMed=8516298; DOI=10.1073/pnas.90.12.5539;
RA   Johnson M.R., Look A.T., DeClue J.E., Valentine M.B., Lowy D.R.;
RT   "Inactivation of the NF1 gene in human melanoma and neuroblastoma cell
RT   lines without impaired regulation of GTP.Ras.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5539-5543(1993).
//
RX   PubMed=10935473; DOI=10.1038/sj.neo.7900010;
RA   Kong X.-T., Valentine V.A., Rowe S.T., Valentine M.B., Ragsdale S.T.,
RA   Jones B.G., Wilkinson D.A., Brodeur G.M., Cohn S.L., Look A.T.;
RT   "Lack of homozygously inactivated p73 in single-copy MYCN primary
RT   neuroblastomas and neuroblastoma cell lines.";
RL   Neoplasia 1:80-89(1999).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=18923524; DOI=10.1038/nature07399;
RA   Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M.,
RA   Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A.,
RA   Hayashi Y., Mano H., Ogawa S.;
RT   "Oncogenic mutations of ALK kinase in neuroblastoma.";
RL   Nature 455:971-974(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//